SCHEDULE 13G/A: Oramed Pharmaceuticals Discloses 9.9% Passive Stake in Scilex Holding Company

Oramed Pharmaceuticals Inc. has filed an amended Schedule 13G, disclosing a 9.9% beneficial ownership stake in Scilex Holding Company, comprising common stock and exercisable warrants, affirming a passive investment intent.

Summary

• Oramed Pharmaceuticals Inc. reported beneficial ownership of 732,717 shares of Scilex Holding Company Common Stock as of March 31, 2025.
• This ownership represents 9.9% of Scilex Holding Company's outstanding Common Stock.
• The total beneficially owned shares consist of 350,000 shares of common stock and 382,717 shares issuable upon the exercise of warrants exercisable within 60 days of the filing date.
• The percentage of class beneficially owned is calculated based on 6,951,796 shares of Common Stock outstanding as of March 25, 2025, as represented by Scilex Holding Company, plus the 382,717 warrant shares held by Oramed.
• Oramed Pharmaceuticals Inc. holds sole voting power and sole dispositive power over all 732,717 beneficially owned shares.
• The filing certifies that the securities were not acquired and are not held for the purpose or effect of changing or influencing the control of Scilex Holding Company.

Sentiment

Score: 5

Explanation: Neutral. This is a routine regulatory filing disclosing a significant ownership stake, not a performance update or strategic announcement that would inherently carry positive or negative sentiment.

Positives

• The filing provides transparency regarding a significant institutional holding in Scilex Holding Company, which can be viewed as a vote of confidence by a major investor.
• The explicit statement of passive investment intent clarifies that Oramed Pharmaceuticals is not seeking to influence or change control of Scilex Holding Company.

Negatives

• No specific negative financial or operational details are disclosed in this ownership filing, as it is a routine regulatory disclosure.

Risks

• The document itself does not detail specific risks related to Scilex Holding Company's operations or financial health, as its purpose is to disclose beneficial ownership.

Future Outlook

The document is a beneficial ownership disclosure and does not contain forward-looking statements or guidance regarding Scilex Holding Company's future performance or Oramed Pharmaceuticals Inc.'s investment strategy beyond the current holding.

Management Comments

• Avraham Gabay, Chief Financial Officer of Oramed Pharmaceuticals Inc., certified that the securities were not acquired and are not held for the purpose or with the effect of changing or influencing the control of the issuer, nor in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing indicates a significant passive investment by Oramed Pharmaceuticals, a Delaware-based pharmaceutical company, in Scilex Holding Company, which operates in the same broader healthcare/pharmaceutical sector. Such cross-holdings can sometimes signal strategic alliances or simply portfolio diversification within the industry, though this filing explicitly states it's not for control purposes.

Comparison to Industry Standards

• As a Schedule 13G filing, this document primarily serves as a disclosure of beneficial ownership and does not provide performance metrics for comparison against industry standards or specific comparable companies or projects. It merely states Oramed's significant stake in Scilex.

Stakeholder Impact

• Shareholders of Scilex Holding Company: Provides transparency regarding a significant institutional investor's stake, which could be viewed positively as a vote of confidence or simply as a disclosure of a large holder.
• Shareholders of Oramed Pharmaceuticals Inc.: Informs them of a significant investment in another publicly traded company, reflecting Oramed's asset allocation.

Next Steps

• The document does not outline any specific future actions, events, or milestones for either Scilex Holding Company or Oramed Pharmaceuticals Inc. beyond the filing itself.

Key Dates

Keywords

Scilex Holding Company, Oramed Pharmaceuticals, Schedule 13G, beneficial ownership, common stock, warrants, SEC filing, institutional ownership, pharmaceuticals, biotechnology